Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
US — Healthcare Sector
Automate Your Wheel Strategy on CTNM
With Tiblio's Option Bot, you can configure your own wheel strategy including CTNM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CTNM
- Rev/Share 0.0
- Book/Share 6.6184
- PB 1.6892
- Debt/Equity 0.0335
- CurrentRatio 24.5133
- ROIC 0.2018
- MktCap 313504484.0
- FreeCF/Share -1.8066
- PFCF -6.7012
- PE -5.0916
- Debt/Assets 0.0314
- DivYield 0
- ROE -0.2975
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CTNM | Leerink Partners | -- | Outperform | -- | $20 | Sept. 25, 2025 |
| Initiation | CTNM | William Blair | -- | Outperform | -- | -- | June 20, 2025 |
| Initiation | CTNM | Robert W. Baird | -- | Outperform | -- | $32 | Oct. 22, 2024 |
News
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 235.81%: Read This Before Placing a Bet
CTNM
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 235.8% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
About Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
- IPO Date
- Website https://www.contineum-tx.com
- Industry Biotechnology
- CEO Carmine N. Stengone MBA, MS
- Employees 41
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.